Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eptifibatide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.82 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.82 |
| ▸ | ITGAV | P06756 | 1/20 | 0.82 |
| ▸ | LDLR | P01130 | 8/20 | 0.56 |
| ▸ | PCSK9 | Q8NBP7 | 8/20 | 0.56 |
| ▸ | TSLP | Q969D9 | 9/20 | 0.54 |
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
| ▸ | MC5R | P33032 | 1/20 | 0.53 |
| ▸ | MC3R | P41968 | 1/20 | 0.53 |
| ▸ | MC1R | Q01726 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eptifibatide SCHEMBL15781 | 1.00 | ITGB3 (0.82) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL571287 | 1.00 | ITGB3 (0.82) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL29398425 | 1.00 | ITGB3 (0.82) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL7107217 | 0.99 | ITGB3 (0.81) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL21753462 | 0.99 | ITGB3 (0.81) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL1890434 | 0.98 | ITGB3 (0.80) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| SCHEMBL24433365 | 0.98 | ITGB3 (0.81) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| SCHEMBL22193885 | 0.98 | ITGB3 (0.81) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL2830072 | 0.97 | ITGB3 (0.78) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| Eptifibatide SCHEMBL21753468 | 0.96 | ITGB3 (0.76) | ITGB3ITGAVITGA2BLDLRPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850285-B2 | Process for preparing eptifibatide | LAURUS LABS LIMITED (IN) | 2017-12-26 | — | — | US | disclosed |
| US-20160017002-A1 | Process for Preparing Eptifibatide | LAURUS LABS LIMITED (IN) | 2016-01-21 | — | — | US | disclosed |
| US-9156885-B2 | Process for preparing eptifibatide | LAURUS LABS PRIVATE LTD. (IN) | 2015-10-13 | — | — | US | disclosed |
| US-20140163203-A1 | PROCESS FOR PREPARING EPTIFIBATIDE | LAURUS LABS PRIVATE LIMITED (IN) | 2014-06-12 | — | — | US | disclosed |
| WO-2013057736-A2 | PREPARATION OF EPTIFIBATIDE PEPTIDE | EMCURE PHARMACEUTICALS LIMITED (IN) | 2013-04-25 | — | — | WO | disclosed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2013014527-A1 | PROCESSES FOR PREPARING EPTIFIBATIDE | LAURUS LABS PRIVATE LIMITED (IN) | 2013-01-31 | — | — | WO | disclosed |
| EP-2204383-B1 | Processes for preparing eptifibatide and pertinent intermediate compounds | MILLENNIUM PHARM INC (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2204383-A1 | Processes for preparing eptifibatide and pertinent intermediate compounds | Millennium Pharmaceuticals, Inc. (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| EP-1735345-B1 | PROCESSES FOR PREPARING EPTIFIBATIDE AND PERTINENT INTERMEDIATE COMPOUNDS | MILLENNIUM PHARM INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2005100381-A2 | PROCESSES FOR PREPARING EPTIFIBATIDE AND PERTINENT INTERMEDIATE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | ITGB3 913/4885ITGA2B 702/4885ITGAV 730/4885 |
| US-20140163203-A1 | PROCESS FOR PREPARING EPTIFIBATIDE | PTGER4, VIP, TBXA2R | ITGB3 863/4885ITGA2B 824/4885ITGAV 1188/4885 |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | ITGB3 913/4885ITGA2B 702/4885ITGAV 730/4885 |
| US-20160017002-A1 | Process for Preparing Eptifibatide | PTGER4, VIP, TBXA2R | ITGB3 863/4885ITGA2B 824/4885ITGAV 1188/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | ITGB3 933/4885ITGA2B 915/4885ITGAV 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.